Two-stage phase II oncology designs using short-term endpoints for early stopping
Two-stage phase II oncology designs using short-term endpoints for early stopping
Phase II oncology trials are conducted to evaluate whether the tumour activity of a new treatment is promising enough to warrant further investigation. The most commonly used approach in this context is a two-stage single-arm design with binary endpoint. As for all designs with interim analysis, its efficiency strongly depends …